文献速递前列腺增生与排尿功能障碍小儿泌尿与泌尿修复

大剂量维生素D补充对比索利那新或标准泌尿疗法治疗儿童干性膀胱过度活动症的疗效与安全性:一项随机临床试验

Efficacy and Safety of High-Dose Vitamin D Supplementation vs Solifenacin or Standard Urotherapy for Overactive Bladder Dry in Children: A Randomized Clinical Trial.
PubMed 文献 · J Urol · 2023-10-23

在中国一家学术中心开展三臂随机临床试验,303例干性膀胱过度活动症患儿随机接受8周大剂量维生素D3滴剂(2400 IU/d)联合标准泌尿疗法、索利那新(5-10 mg/d)联合标准泌尿疗法或单用标准泌尿疗法。维生素D联合组排尿次数改善优于索利那新联合组和单用组,生活质量和儿童下尿路症状评分改善也最大,治疗中出现的不良事件风险未增加。

要点

  • 维生素D联合组排尿次数改善优于索利那新联合组(中位差3.0,95%CI 2.0-3.5,P<.001)。
  • 维生素D联合组排尿次数改善优于单用标准泌尿疗法组(中位差4.0,95%CI 3.0-5.0,P<.001)。
  • 维生素D联合组生活质量和儿童下尿路症状评分改善最大,不良事件风险未增加。

核心结论

  • 大剂量维生素D补充联合标准泌尿疗法对儿童干性膀胱过度活动症有效且耐受良好,提示其可能作为该人群的一种新治疗选择。

研究设计与样本

  • 在中国一家学术中心于2023年1月至2023年6月开展的三臂随机临床试验,共纳入303例合格患者。
  • 患者随机接受8周大剂量维生素D补充(维生素D3滴剂制成软胶囊,2400 IU/d)联合标准泌尿疗法(VDS+SU组,n=100)、索利那新(5-10 mg/d)联合标准泌尿疗法(SOL+SU组,n=102)或单用标准泌尿疗法(SU组,n=101)。
  • 主要结局为排尿频率减少,次要结局包括尿急、夜尿、生活质量评分、儿童下尿路症状评分和参与者满意度改善,并记录各组治疗中出现的不良事件。

主要发现

  • 参与者中位年龄82.0个月,基线平均维生素D水平22.64 ng/mL。
  • 干预后VDS+SU组排尿次数改善大于SOL+SU组(中位差3.0;95%CI 2.0至3.5;P<.001)。
  • 干预后VDS+SU组排尿次数改善大于SU组(中位差4.0;95%CI 3.0至5.0;P<.001)。
  • VDS+SU组生活质量和儿童下尿路症状评分改善最大。
  • SOL+SU组与SU组患者满意度相似,VDS+SU组治疗中出现的不良事件风险与其他组相比未增加。

关键数值与推荐

  • VDS+SU组排尿次数改善 vs SOL+SU组中位差3.0(95%CI 2.0至3.5,P<.001),VDS+SU组改善更大。
  • VDS+SU组排尿次数改善 vs SU组中位差4.0(95%CI 3.0至5.0,P<.001),VDS+SU组改善更大。
  • SOL+SU组与SU组患者满意度相似。
  • VDS+SU组治疗中出现的不良事件风险与其他组相比未增加。

临床怎么用

  • 原文结论认为大剂量维生素D补充联合标准泌尿疗法对儿童干性膀胱过度活动症有效且耐受良好,提示其可能作为该人群的一种新治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the efficacy and safety of high-dose vitamin D supplementation (VDS) plus standard urotherapy (SU) in managing overactive bladder dry in children. MATERIALS AND METHODS: A 3-arm, randomized clinical trial was performed at an academic center in China between January 2023 and June 2023. Eligible patients (n=303) were randomized to receive 8 weeks of high-dose VDS (vitamin D3 drops encapsulated as soft capsules, 2400 IU/d) plus SU (VDS + SU group; n=100), solifenacin (5-10 mg/d) plus SU (SOL + SU group; n=102), or SU alone (SU group; n=101). Reduction in voiding frequency was the primary outcome. Secondary outcomes encompassed improvement in urgency, nocturia, quality of life score, pediatric lower urinary tract symptom score, and participant satisfaction. Treatment-emergent adverse events were recorded within each group. RESULTS: Participants had a median age of 82.0 months and their baseline mean vitamin D level was 22.64 ng/mL. The VDS + SU group showed greater improvements in voids/d than the SOL + SU group (median difference 3.0; 95% CI, 2.0 to 3.5; P < .001) and the SU group (median difference 4.0; 95% CI, 3.0 to 5.0; P < .001) after intervention. The VDS + SU group also showed the greatest improvement in quality of life and pediatric lower urinary tract symptom scores. Patient satisfaction was similar between the SOL + SU and SU groups. The VDS + SU group did not exhibit a heightened risk of treatment-emergent adverse events compared to the other groups. CONCLUSIONS: High-dose VDS plus SU was effective and well-tolerated in managing overactive bladder dry in children, suggesting its potential as a novel therapeutic option for this population.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Chen H, Zhang Z, Wu S, et al. Efficacy and Safety of High-Dose Vitamin D Supplementation vs Solifenacin or Standard Urotherapy for Overactive Bladder Dry in Children: A Randomized Clinical Trial. J Urol. 2023. PMID: 37871329. doi:10.1097/JU.0000000000003763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。